Meeting
2021 ASCO Annual Meeting
Treatment free remission (TFR) and overall response rate (ORR) results in patients with relapsed/refractory Waldenstrom’s macroglobulinemia (WM) treated with CLR 131.
Authors
Sikander Ailawadhi
Mayo Clinic, Jacksonville, FL
Sikander Ailawadhi , Asher Alban Akmal Chanan-Khan , Jennifer Layton Peterson , Jarrod Longcor , Katherine Oliver , Matthew Francis Brown , John Friend , Damian Jonathan Green
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT02952508
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 7561)
DOI
10.1200/JCO.2021.39.15_suppl.7561
Abstract #
7561
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Five-year follow-up update of defined-composition CD19 CAR T-cell therapy for relapsed/refractory CLL.
First Author: Emily C. Liang
Poster
2020 ASCO Virtual Scientific Program
Phase I study of tazemetostat, an enhancer of zeste homolog-2 inhibitor, in pediatric pts with relapsed/refractory integrase interactor 1-negative tumors.
First Author: Susan N. Chi
Poster
2024 ASCO Annual Meeting
Ipatasertib in patients with AKT1/2/3 mutation-positive (AKTmut) tumors: TAPISTRY study.
First Author: David Morgan Thomas
Poster
2024 ASCO Annual Meeting
Final results of CORE-001: A phase-2, single arm study of cretostimogene grenadenorepvec in combination with pembrolizumab in patients with BCG-unresponsive, non-muscle invasive bladder cancer with carcinoma in situ.
First Author: Roger Li